Lynn E. S̄pitler

St. Mary's Medical Center — United States

Immunology and Microbiology · Life Sciences

36h-index7.0kcitations145works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(38), CAR-T cell therapy research(36), Monoclonal and Polyclonal Antibodies Research(22), Virus-based gene therapy research(17), Cutaneous Melanoma Detection and Management(16)

Publications144 total

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
Cancer·2019· 73 citedOpen Access
A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.
Journal of Clinical Oncology·2017· 11 cited
A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma
Annals of Oncology·2016· 7 cited
Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21.
Journal of Clinical Oncology·2016· 3 cited
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses
OncoImmunology·2015· 36 citedOpen Access
3335 Intralesional administration of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma induces durable tumor responses
European Journal of Cancer·2015· 1 cited
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Journal of Clinical Oncology·2015· 2.5k citedOpen Access
Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.
Journal of Clinical Oncology·2015· 66 cited
Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC).
Journal of Clinical Oncology·2015· 17 cited
BCG, Levamisole and Transfer Factor in the Treatment of Cancer
Progress in tumor research·2015· 11 cited
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
Journal for ImmunoTherapy of Cancer·2014· 22 citedOpen Access
Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma
American Journal of Clinical Oncology·2014· 10 citedOpen Access
Calm Study: Secondary Endpoints of a Phase Ii Study of a Novel Oncolytic Immunotherapeutic Agent, Coxsackievirus A21, Delivered Intratumorally in Patients with Advanced Malignant Melanoma
Annals of Oncology·2014· 4 citedOpen Access
Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma.
Journal of Clinical Oncology·2014· 6 cited
CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma.
Journal of Clinical Oncology·2014· 28 cited
Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Journal of Clinical Oncology·2014· 44 cited
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Journal of Clinical Oncology·2013· 84 cited
CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma.
Journal of Clinical Oncology·2013· 12 cited
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Journal of Clinical Oncology·2013· 117 cited
Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma
American Journal of Clinical Oncology·2013· 38 cited
page 1 of 8Next →

Frequent Co-authors

H. Hugh Fudenberg(12), Alan S. Levin(7), Robert Hans Ingemar Andtbacka(5), Howard L. Kaufman(5), Frances A. Collichio(4), Thomas Amatruda(4), Neil Senzer(4), Jason Chesney(4), Keith A. Delman(4), Igor Puzanov(4), Yining Ye(4), Robert S. Coffin(4), Joseph Wybran(4), Robert Weber(4), Brendan D. Curti(3), Gregory A. Daniels(3), Susan Doleman(3), Ari M. Vanderwalde(3), R P Mischak(3), Jose Lutzky(3)